The Federal Trade Commission said that there are no ongoing talks with Amgen Inc. to resolve a legal challenge to it $27.8 billion takeover of Horizon Therapeutics Plc after the agency rejected a settlement overture made earlier this year.
During a hearing Wednesday in the FTC’s in-house court, agency lawyer Nathan Brenner said the FTC engaged in settlement discussions earlier in the case and remains “open to hearing proposals.”
David Marriott, a lawyer for Amgen, acknowledged the earlier talks but said the company believes there is “no anticompetitive effect” by the deal to fix.
Read the full story on Bloomberg here.